临床路径管理对结节性甲状腺肿单病种付费患者住院费用及费用结构的影响  

Influence of Clinical Pathway Management on Hospitalization Expenses and Expense Structure of Nodular Goiter Patients with Single Disease Payment

作　　者：胡云鹤[1] 郭嘉奇 樊美娜[1] 

机构地区：[1]中国医学科学院肿瘤医院,北京市100021 [2]首都医学大学附属北京世纪坛医院,北京市100038

出　　处：《中国病案》2018年第2期51-55,共5页Chinese Medical Record

摘　　要：目的观察临床路径管理对结节性甲状腺肿单病种付费患者住院费用及费用结构的影响。方法选择131例2013年-2016年收治的结节性甲状腺肿单病种付费患者,将其中42例纳入临床路径管理的患者列为观察组,其余89例患者列入对照组。比较两组患者住院总费用及药费、材料费、检查费、治疗费。结果两组患者住院总费用及药费、材料费、检查费、治疗费相比P>0.05。分层比较中2013年两组患者检查费、治疗费相比,P<0.05;其余年份指标两组相比P>0.05。结论临床路径管理对结节性甲状腺肿单病种付费患者住院费用及费用结构无明显影响。Objective To investigate the influence of clinical pathway management on hospitalization expenses and expense structure of nodular goiter patients with Single disease payment. Methods 131 nodular goiter patients with Single disease payment from 2013 to 2016 were chose into this study, and 42 patients were included into clinical pathway management（observation group）, and the other were control group. The total hospitalization expenses, medical expenses, material fees, examination fees and treatment fees were compared between the two groups. Results In 2013, the difference of examination fees and treatment fees for patients in two groups were significant, P〈0.05. But in any other years or fees, all P〈0.05. Conclusion Clinical pathway management has no significant influence on the hospitalization expenses and expense structure for nodular goiter patients with single disease payment.

关 键 词：临床路径 北京医保 结节性甲状腺肿 单病种付费 医疗费用 

分 类 号：R197.323[医药卫生—卫生事业管理]